Jasper Therapeutics, Inc.
JSPRDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
3
Next Catalyst
Aug 12, 2026
14dMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
JSPR Earnings Report
EPS Est: $-0.38 | FQ end 2026-06
2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How JSPR's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Briquilimab | Phase 2 | Chronic Spontaneous Urticaria | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Jasper Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Jasper Therapeutics, Inc.'s (JSPR) pipeline across Phase 2. Its lead program is Briquilimab (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Jasper Therapeutics, Inc.'s next FDA catalyst?→
Jasper Therapeutics, Inc.'s (JSPR) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track JSPR biotech catalysts?→
Add JSPR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Jasper Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.